← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Vasopressin

FDA approved · Rx

Peptide hormone vasopressor

Also known as: Vasostrict, antidiuretic hormone, Vasopressin In 0.9% Sodium Chloride, ARGIPRESSIN, Argipressine, Arginine vasopressin, Vasopressin injection, Argipresina, Argipressina, Argipressinum

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 433 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Vasopressin, also called antidiuretic hormone, is a naturally occurring nine amino acid peptide made in the hypothalamus and released by the pituitary gland. It acts on V1 receptors in blood vessel walls to cause constriction and raise blood pressure, and on V2 receptors in the kidney to help the body retain water.

What the evidence shows

Automatic summaryHuman trials

Vasopressin (Vasostrict) is FDA approved for raising blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines, and it is backed by hundreds of registered trials and a very large published literature. Uses outside its approved indications vary in how well they are supported.

Key facts

Molecular formula
C46H65N15O12S2
Molecular weight
1084.2 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

433registered studies
Phase 4most advanced phase
53completed (sample)
11recruiting (sample)

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Phase 3TerminatedNCT04064346

Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

CompletedNCT00816127

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

Phase 2Not Yet RecruitingNCT07328529

Vasopressin in Traumatic Hemorrhagic Shock Study

Phase 3CompletedNCT00379522

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

38,029papers referencing Vasopressin

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.

Crit Care Med2013

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Intensive Care Med2013

Stress and disorders of the stress system.

Nat Rev Endocrinol2009

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

Crit Care Med2004

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.